Valuation: Alnylam Pharmaceuticals, Inc.

Market Cap 29.33B 25.37B 23.69B 21.73B 40.88B 2,791B 41.53B 278B 109B 1,399B 110B 108B 4,626B P/E 2026 *
31.9x
P/E 2027 * 21.5x
Enterprise Value 26.76B 23.14B 21.61B 19.83B 37.29B 2,546B 37.88B 254B 99.53B 1,276B 100B 98.28B 4,220B EV / Sales 2026 *
4.86x
EV / Sales 2027 * 3.56x
Free-Float
99.82%
Yield 2026 *
-
Yield 2027 * -
1 day+1.43%
1 week+6.66%
Current month+6.66%
1 month-32.24%
3 months-25.71%
6 months-33.20%
Current year-44.88%
1 week 208.04
Extreme 208.035
234
1 month 197.81
Extreme 197.81
322.49
Current year 197.81
Extreme 197.81
427.05
1 year 197.81
Extreme 197.81
495.55
3 years 141.98
Extreme 141.975
495.55
5 years 117.58
Extreme 117.58
495.55
10 years 31.38
Extreme 31.38
495.55
Manager TitleAgeSince
Chief Executive Officer 63 2021-12-31
Director of Finance/CFO 58 2019-08-12
Chief Tech/Sci/R&D Officer - 2023-03-31
Director TitleAgeSince
Director/Board Member 80 2012-04-22
Chairman 65 2023-01-04
Director/Board Member 72 2015-12-17
Date Insider Type Main position Quantity % Market Cap.
6/1/26 Free

Director

4,393 0.0033%
2/27/26 Fiscal year

Chief Executive Officer

11,842 0.0090%
2/27/26 Fiscal year

Chief Technology Officer

8,443 0.0064%
Change 5-day change 1-year change 3-year change Capi.($)
+1.43%+6.66%-50.06%+18.59% 29.33B
-0.52%+3.21%+89.52%+127.32% 1,057B
+0.88%+1.13%+49.56%+49.69% 625B
+0.89%-1.95%+24.23%+64.44% 435B
+0.71%+3.87%+49.07%+37.85% 363B
+0.64%-0.49%+33.94%+40.01% 296B
+0.39%-5.83%+8.92%+7.85% 249B
+1.51%+6.69%+42.58%+57.57% 222B
+3.92%-0.46%-5.56%-52.32% 209B
+1.80%+2.30%+11.56%+66.35% 165B
Average +1.16%+1.45%+25.37%+41.74% 365.01B
Weighted average by Cap. +0.66%+1.26%+47.93%+64.26%

Financials

2026 *2027 *
Net sales 5.5B 4.76B 4.45B 4.08B 7.67B 524B 7.79B 52.16B 20.47B 263B 20.67B 20.21B 868B 7B 6.05B 5.65B 5.19B 9.75B 666B 9.91B 66.32B 26.03B 334B 26.28B 25.7B 1,104B
Net income 952M 824M 769M 706M 1.33B 90.63B 1.35B 9.02B 3.54B 45.43B 3.58B 3.5B 150B 1.41B 1.22B 1.14B 1.05B 1.97B 135B 2B 13.41B 5.26B 67.5B 5.31B 5.2B 223B
Net Debt -2.57B -2.23B -2.08B -1.91B -3.59B -245B -3.65B -24.4B -9.58B -123B -9.67B -9.46B -406B -4.44B -3.84B -3.58B -3.29B -6.18B -422B -6.28B -42.04B -16.5B -212B -16.66B -16.29B -699B
Logo Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals, Inc. is a biopharmaceutical company specializing in the development, manufacture, and commercialization of therapeutics based on RNA interference technology, The company offers treatments for rare and chronic diseases, including cardiovascular diseases, acute hepatic porphyria, hypercholesterolemia, and transthyretin amyloidosis with neurological involvement. At the end of 2025, Alnylam Pharmaceuticals, Inc. had a portfolio of 5 products on the market and several candidates in clinical development. Net sales are distributed geographically as follows: the United States (69.2%), Europe (21.8%) and other (9%).
Employees
2,500
Date Price Change Volume
26-08-07 US$219.20 +1.43% 1,735,992
26-08-06 US$216.12 -5.51% 2,274,559
26-08-05 US$228.72 +4.44% 2,734,599
26-08-04 US$219.00 -0.60% 3,107,854
26-08-03 US$220.33 +7.21% 3,400,184
Trader
Investor
Global
Quality
ESG MSCI
AA
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
27
Last Close Price
219.20USD
Average target price
375.76USD
Spread / Average Target
+71.42%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. ALNY Stock